Cooperative Program in Translational Research for Neuromuscular Disease (U01) | Apply Online

Opportunity Summary:

The Cooperative Program in Translational Research for Neuromuscular Disease (U01) is a National Institutes of Health funding opportunity led jointly by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Its central aim is to push promising therapeutic concepts for neuromuscular diseases through the key preclinical steps needed to reach readiness for first-in-human testing. In practical terms, this program is meant to close the gap between basic discoveries and an actual therapeutic candidate by funding the kinds of development work that often sit between academic proof-of-concept and an industry-style preclinical package.

The opportunity is specifically designed for therapy-directed projects that already have a therapeutic lead in hand. The lead has to show demonstrated activity against the intended disease target, meaning applicants should not be coming in with only a hypothesis or an untested idea. Supported work includes preclinical optimization and rigorous testing that strengthens the case for moving a candidate toward the clinic. A defining requirement is that the project must be advanced enough that, by the end of the award period, the investigators can submit either an Investigational New Drug (IND) application (typically for drugs and biologics) or an Investigational Device Exemption (IDE) application (for devices) to the U.S. Food and Drug Administration. That endpoint signals the program is not about generating early signals, but about producing a credible regulatory-ready package.

Just as important are the activities the program does not fund. It explicitly excludes early-stage therapeutic discovery work such as high-throughput screening, which is usually the phase where large numbers of compounds are tested to find initial “hits.” It also excludes clinical research, basic research, and studies focused on disease mechanisms. In other words, it is not intended to explain how a disease works or to explore new biology in an open-ended way, and it is not intended to run human trials. It is meant for the translational middle ground: candidate refinement, preclinical efficacy and safety-enabling studies, and the planning and documentation needed to be positioned for FDA submission.

This FOA uses the U01 cooperative agreement mechanism, which differs from a standard grant in that NIH staff are expected to be actively involved. The program is milestone-driven, meaning investigators propose clear, go/no-go decision points and measurable deliverables, and NIH program staff participate in shaping the project plan and monitoring progress. This structure is meant to keep projects tightly focused on development objectives, enable course corrections when needed, and ensure that funded work stays aligned with the ultimate goal of IND/IDE submission rather than drifting into exploratory research.

From an administrative standpoint, the opportunity is listed as Funding Opportunity Number PAR-08-229 under the NIH discretionary grants category, with activity in the health domain. It is associated with CFDA numbers 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders) and 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). There is no cost sharing or matching requirement, which means applicants are not required to contribute non-federal funds as a condition of the award.

Eligibility is broad and includes many types of organizations: public and private institutions of higher education, nonprofits (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), state and local governments, tribal governments and tribal organizations, independent school districts, public housing authorities, and special district governments. The FOA also notes additional eligible groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, and non-U.S. entities (foreign organizations), as well as regional organizations. This wide eligibility reflects an intent to attract strong translational teams wherever they exist, including academic labs, nonprofits, and industry partners capable of performing preclinical development work.

Key dates shown in the listing include a posted date of December 3, 2008, with later administrative updates; the original closing date is listed as September 7, 2011, and the current closing date as May 7, 2011, with an archive date of June 7, 2011. The full announcement and requirements were provided through the NIH Grants Guide, and the listing includes NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.

Overall, this funding opportunity is best understood as a focused translational pipeline program for neuromuscular disease therapeutics: it funds projects that already have an active lead, supports the practical preclinical work needed to mature that lead into a development candidate, and expects teams to finish with a package strong enough to support an IND or IDE submission, all under a milestone-based cooperative agreement with ongoing NIH involvement.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: NINDS Cooperative Program in Translational Research Single Component Research Projects (U01)

Previous opportunity: International Research Collaboration on Alcohol and Alcoholism (U01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 08 229

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 08 229) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 08 229", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.